Showing results (61-70 of 339) with videos related to
Sort By:
Pageof 34
Stroke|February 8, 2003
Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset?David M Kent, Robin Ruthazer, Harry P SelkerNeurology|May 29, 2013
Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease [RETIRED]: report of the Guideline Development Subcommittee of the American Academy of NeurologyMelissa J Armstrong, Gary Gronseth, David C Anderson, et al.Frontiers in Neurology|October 13, 2012
Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA CohortMichael T Mullen, Steven R Messé, Scott E Kasner, et al.Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|February 5, 2022
Delays in the Identification and Assessment of in-Hospital Stroke PatientsStephanie Cummings, Scott E Kasner, Michael Mullen, et al.Frontiers in Neurology|November 20, 2018
Association Between Anxiety, Depression, and Post-traumatic Stress Disorder and Outcomes After Ischemic StrokeLaura A Stein, Emily Goldmann, Ahmad Zamzam, et al.Stroke|February 24, 2017
Risk of Pulmonary Embolism After Cerebral Venous ThrombosisAva L Liberman, Alexander E Merkler, Gino Gialdini, et al.Stroke|March 2, 2018
Geographic Modeling to Quantify the Impact of Primary and Comprehensive Stroke Center Destination PoliciesMichael T Mullen, William Pajerowski, Steven R Messé, et al.Nature Reviews. Disease Primers|May 19, 2016
Patent foramen ovaleShunichi Homma, Steven R Messé, Tatjana Rundek, et al.Trials|May 24, 2008
Competing risk and heterogeneity of treatment effect in clinical trialsDavid M Kent, Alawi Alsheikh-Ali, Rodney A HaywardAnnals of Internal Medicine|December 2, 2024
A Framework for Considering the Value of Race and Ethnicity in Estimating Disease RiskMadison Coots, Soroush Saghafian, David M Kent, et al.Pageof 34